The consumer health division has gone – it was demerged as Haleon in 2023, which ended the debate about whether GSK required a bigger break-up. The cost was a trim for shareholders’ dividends but Walmsley plainly had to deploy the scissors. But the current suspicion around GSK lies in doubts about whether Walmsley’s targets – intended to signal “a step change in performance versus our history”, as she put it in 2021 – can be achieved. Luke Miels, the chief commercial officer, has looked the likely successor ever since Walmsley hired him from AstraZeneca. Yes, as she says, she’s leaving GSK as a stronger business – few doubt that a corner has been turned.